Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-8

The tube lab market for me is primarily in biobanks. These groups have all been hard hit by COVID and unlikely to have much activity. While I should have seen this coming as I am in the industry and sell to said biobanks I didnt sell at 7 as i underestimated the normalisation time for these groups. I would say things are starting to improve in the US so we should see more opportunities over the next 12 months as things normalise. Dont hold your breath or the next 3-6 though.